Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
12.11.2021
Medicines
12.11.2021
The drug will be admitted to hospitals by the end of 2021.
MOSCOW, November 12. /tass/. Areplivir, the first domestic direct-acting injectable drug for the treatment of COVID-19 He has been registered and will begin to be admitted to hospitals by the end of 2021, the press service of the developer, Promomed Group, told TASS.ON THIS TOPIC
"The first domestic direct-acting intravenous antiviral drug Areplivir (favipiravir) has received a registration certificate and will be admitted to hospitals in all regions by the end of the year. With its development by Promomed Group of Companies He responded to the urgent need of domestic healthcare for hospital-based COVID—19 therapy," the press service said.
Full-scale production of the drug on the basis of JSC Biochemik and its delivery to medical institutions in the country will begin in December 2021. The company noted that Promomed He was the first in the world to create an injectable form of favipiravir, despite the fact that the substance is an insoluble powder. A multicenter clinical trial led by Dmitry Pushkar, Academician of the Russian Academy of Sciences, confirmed the effectiveness and safety of the new drug when used in hospitals.
The oral form of Areplivir It is included in the current recommendations at both outpatient and inpatient stages. It is expected that the injectable form will also be included in the recommendations as more effective for the treatment of hospitalized patients. The final decision will be made by the Ministry of Health of the Russian Federation during the next revision of the interim guidelines for the prevention, diagnosis and treatment of new coronavirus infection, Promomed emphasized. According to Sergey Avdeev, chief pulmonologist at the Ministry of Health of the Russian Federation, Corresponding Member of the Russian Academy of Sciences, so far the only antiviral drug for parenteral administration has been a foreign drug, which is not only expensive, but also inaccessible.
"The emergence of an effective domestic antiviral drug for parenteral administration, while widely available, can turn the tide in the fight against the pandemic. The injectable form of the drug is characterized not only by 100% bioavailability, but also by more intensive penetration and distribution in cells, longer retention of therapeutic concentration in tissues, and an improved safety profile. This should significantly increase the effectiveness of the treatment at the hospital stage," Avdeev said.
The company also recalled that during a recent meeting, Russian President Vladimir Putin announced the introduction of new domestic drugs to combat COVID-19. One of the first such drugs was the injectable Areplivir.
Sources
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
